-+ 0.00%
-+ 0.00%
-+ 0.00%

SANOFI - CENRIFKI (TOLEBRUTINIB) APPROVED IN THE EU AS THE FIRST DISABILITY-TARGETING MEDICINE FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS WITHOUT RELAPSES

Reuters·06/23/2026 05:00:23

Please log in to view news